Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema:

• following central retinal vein occlusion or

• following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage and

• only if the manufacturers of ranibizumab (branded or biosimilar) provide it at a discount level no lower than the discount agreed in the patient access scheme.

People currently receiving ranibizumab whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.